Exploring Preclinical Characterization of IKS04 in GI Cancer & Assessing Impact of Unconjugated Antibody Co-Dosing on Tumor Penetration
- Introducing IKS04 ultra-low DAR approach with a highly potent payload targeting CA242 in GI cancer
- Explaining rationale and preclinical data for co-dosing with antibodies to improve tumor uptake of potent payload ADCs
- Reviewing the preclinical profile of IKS04 and highlighting future plans for clinical investigation